Summary

Hypertension is a major public health concern worldwide because of its rising prevalence and concomitant risks of cardiovascular diseases. Coping strategies may encompass a full spectrum of clinical, epidemiological, experimental, and technological factors to inspire front-line practices and shape critical thinking. This entry collection aims to assemble entries of wealthy topics related to clinical, therapeutic, and population sciences of hypertension and cardiovascular diseases that could inform research scientists and healthcare professionals.

Expand All
Entries
Topic Review
Genetic RyR2 Disease
The ryanodine receptor (RyR2) has a critical role in controlling Ca2+ release from the sarcoplasmic reticulum (SR) throughout the cardiac cycle. RyR2 protein has multiple functional domains with specific roles, and four of these RyR2 protomers are required to form the quaternary structure that comprises the functional channel. Numerous mutations in the gene encoding RyR2 protein have been identified and many are linked to a wide spectrum of arrhythmic heart disease. Gain of function mutations result in a hyperactive channel that causes excessive spontaneous SR Ca2+ release, but rare hypoactive loss of function mutations have also been described.
  • 531
  • 17 Aug 2022
Topic Review
Iron Supplementation in Heart Failure
Iron deficiency is a significant comorbidity of heart failure (HF), defined as the inability of the myocardium to provide sufficient blood flow. However, iron deficiency remains insufficiently detected. Iron-deficiency anemia, defined as a decrease in hemoglobin caused by iron deficiency, is a late consequence of iron deficiency, and the symptoms of iron deficiency, which are not specific, are often confused with those of HF or comorbidities. HF patients with iron deficiency are often rehospitalized and present reduced survival. The correction of iron deficiency in HF patients is associated with improved functional capacity, quality of life, and rehospitalization rates. Because of the inflammation associated with chronic HF, which complicates the picture of nutritional deficiency, only the parenteral route can bypass the tissue sequestration of iron and the inhibition of intestinal iron absorption. Given the negative impact of iron deficiency on HF progression, the frequency and financial implications of rehospitalizations due to decompensation episodes, and the efficacy of this supplementation, screening for this frequent comorbidity should be part of routine testing in all HF patients.
  • 404
  • 18 Aug 2022
Topic Review
New Therapeutic Approaches in Treatment of Dyslipidaemia
Dyslipidaemia is a well-known risk factor for the development of cardiovascular disease. Traditional statin therapy remains the cornerstone therapeutic approach. Ezetimibe showed good but limited results when used in combination with statins. Bempedoic acid has been thoroughly studied in multiple clinical trials, with a reduction in LDL cholesterol by approximately 15%. The first approved monoclonal antibodies for the treatment of dyslipidaemia, PCSK9 inhibitors, are currently used as second-line treatment for patients with unregulated lipid levels on statin or statin combination therapy. A new siRNA molecule, inclisiran, demonstrates great potential, particularly concerning compliance, as it is administered twice yearly and pelacarsen, an antisense oligonucleotide that targets lipoprotein(a) and lowers its levels. Volanesorsen is the first drug that was designed to target chylomicrons and lower triglyceride levels, and olezarsen, the next in-line chylomicron lowering agent, is currently being researched. The newest possibilities for the treatment of dyslipidaemia are ANGPTL3 inhibitors with evinacumab, already approved by the FDA, and EMA for the treatment of familial hypercholesterolemia. 
  • 470
  • 12 Aug 2022
Topic Review
Phenotypes of Arrhythmogenic Cardiomyopathy
Arrhythmogenic Cardiomyopathy (ACM) is a Mendelian disorder that can affect both left and right ventricles. It is most often associated with pathogenic desmosomal variants that can lead to fibrofatty replacement of the myocardium, a pathological hallmark of this disease.
  • 335
  • 11 Aug 2022
Topic Review
Effects of Particulate Matter on Inflammation and Thrombosis
Ambient air pollution has become a common problem worldwide. Exposure to pollutant particles causes many health conditions, having a particular impact on pulmonary and cardiovascular disease. Increased understanding of the pathological processes related to these conditions may facilitate the prevention of the adverse impact of air pollution on our physical health. 
  • 612
  • 04 Aug 2022
Topic Review
Types of Transcatheter Aortic Valve Replacement Devices
Transcatheter aortic valve replacement (TAVR) was originally conceptualized in the early 1990s, largely inspired by the pioneering experiences in the field of percutaneous transluminal coronary angioplasty.
  • 5.7K
  • 03 Aug 2022
Topic Review
Thoracic Aortic Aneurysm and Dissection
The main challenge in diagnosing and managing thoracic aortic aneurysm and dissection (TAA/D) is represented by the early detection of a disease that is both deadly and “elusive”, as it generally grows asymptomatically prior to rupture, leading to death in the majority of cases. Gender differences exist in aortic dissection in terms of incidence and treatment options. Efforts have been made to identify biomarkers that may help in early diagnosis and in detecting those patients at a higher risk of developing life-threatening complications. As soon as the hereditability of the TAA/D was demonstrated, several genetic factors were found to be associated with both the syndromic and non-syndromic forms of the disease, and they currently play a role in patient diagnosis/prognosis and management-guidance purposes.
  • 525
  • 02 Aug 2022
Topic Review
Renal Denervation in the Management of Heart Failure
Norepinephrine (NE) spillover in the kidneys is associated with a worse prognosis. Since the kidneys constitute an integral part of the sympathetic activation feedback loop between the brain, the heart, the vasculature, and the kidneys, the therapies targeting this afferent loop may provide a novel and promising target in the management of patients with heart failure. Renal denervation has evolved from surgical denervation to transcatheter-based technology. This latter technique is a minimally invasive, catheter-based procedure that ablates both the afferent and efferent renal sympathetic nerves. Various catheter-based technologies exist today, including radiofrequency ablation, ultrasound thermal ablation, and chemical ablation utilizing alcohol. Renal denervation has been predominantly studied as a tool for the management of resistant hypertension. 
  • 290
  • 01 Aug 2022
Topic Review
Suicidal Erythrocyte Death in Metabolic Syndrome
Eryptosis is a coordinated, programmed cell death culminating with the disposal of cells without disruption of the cell membrane and the release of endocellular oxidative and pro-inflammatory milieu. While providing a convenient form of death for erythrocytes, dysregulated eryptosis may result in a series of detrimental and harmful pathological consequences highly related to the endothelial dysfunction (ED). Metabolic syndrome (MetS) is described as a cluster of cardiometabolic factors (hyperglycemia, dyslipidemia, hypertension and obesity) that increases the risk of cardiovascular complications such as those related to diabetes and atherosclerosis.
  • 490
  • 01 Aug 2022
Topic Review
Exercise Training Effects on Heart Failure
Heart failure (HF) is a major public health issue worldwide with increased prevalence and a high number of hospitalizations. Patients with chronic HF and either reduced ejection fraction (HFrEF) or mildly reduced ejection fraction (HFmrEF) present vascular endothelial dysfunction and significantly decreased circulating levels of endothelial progenitor cells (EPCs).
  • 434
  • 25 Jul 2022
  • Page
  • of
  • 38

Featured Entry Collections

>>